Crystal Rock Capital Management Has $4.55 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Crystal Rock Capital Management boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 90.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,005 shares of the company’s stock after buying an additional 4,265 shares during the period. IDEXX Laboratories makes up about 2.7% of Crystal Rock Capital Management’s investment portfolio, making the stock its 14th biggest position. Crystal Rock Capital Management’s holdings in IDEXX Laboratories were worth $4,550,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IDXX. Empowered Funds LLC raised its holdings in IDEXX Laboratories by 28.0% in the first quarter. Empowered Funds LLC now owns 1,039 shares of the company’s stock worth $561,000 after purchasing an additional 227 shares during the period. Atomi Financial Group Inc. raised its holdings in shares of IDEXX Laboratories by 3.4% during the first quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock worth $344,000 after acquiring an additional 21 shares during the period. Concurrent Investment Advisors LLC raised its holdings in shares of IDEXX Laboratories by 12.1% during the first quarter. Concurrent Investment Advisors LLC now owns 446 shares of the company’s stock worth $241,000 after acquiring an additional 48 shares during the period. NorthRock Partners LLC raised its holdings in shares of IDEXX Laboratories by 14.6% during the first quarter. NorthRock Partners LLC now owns 527 shares of the company’s stock worth $285,000 after acquiring an additional 67 shares during the period. Finally, QRG Capital Management Inc. raised its holdings in shares of IDEXX Laboratories by 7.4% during the first quarter. QRG Capital Management Inc. now owns 3,725 shares of the company’s stock worth $2,011,000 after acquiring an additional 258 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on IDXX shares. JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Piper Sandler restated a “neutral” rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, BTIG Research started coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Stock Up 0.9 %

IDEXX Laboratories stock opened at $437.30 on Tuesday. The company has a fifty day simple moving average of $471.95 and a 200 day simple moving average of $484.70. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The company has a market cap of $35.81 billion, a P/E ratio of 42.17, a price-to-earnings-growth ratio of 3.78 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter last year, the firm posted $2.53 EPS. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Research analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.